Compare Krispy Kreme Inc (DNUT) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Krispy Kreme Inc vs Medpace Holdings Inc — how do they compare? Krispy Kreme Inc trades at $3.01 (market cap $508.36M), while Medpace Holdings Inc trades at $602 (market cap $16.87B). The key difference: Medpace Holdings Inc is far larger — about 33.2× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays a 3.47% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Krispy Kreme Inc for 45 Days and Medpace Holdings Inc for 14 Days on average.
| DNUT | MEDP | |
|---|---|---|
Market Cap | $508.36M | $16.87B |
Volume | 1,955,706 | 207,570 |
Sector | Consumer Staples | Health |
52-Week High | $4.70 | $630.19 |
52-Week Low | $2.87 | $393.42 |
Typical Hold Time | 45 Days | 14 Days |
Enterprise Value | $1.75B | $16.48B |
Dividend Yield | 3.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Krispy Kreme (DNUT) trades at $3.01, down 0.33% on the day, with a bearish technical signal. The company reported a net loss of $515.77 million in 2025, despite a 75.19% gross margin, and faces legal investigations into fiduciary duties. Revenue declined to $1.52 billion in 2025 from $1.7 billion in 2024.
The outlook is cautious due to persistent losses and legal overhangs, though analyst consensus leans buy. Key risks include profitability challenges and high debt. Upside depends on operational turnaround and new product launches driving growth.
MEDP trades at $604.25, up 0.22% with neutral technical signals and strong fundamental performance. The stock shows robust profitability with 17.67% net income margin and consistent earnings beats in recent quarters. Recent news highlights institutional activity including CEO stock sales and upcoming Q3 2026 earnings report on October 21, 2026. Technical indicators show mixed signals with RSI neutral and ADX bullish, while support sits at $589 and resistance at $629.
MEDP presents a mixed outlook with strong fundamentals offset by high valuations and insider selling. The 21% buy rating from analysts suggests cautious optimism, with $620.44 price target offering 2.7% upside. Key risks include elevated P/E ratio of 35.5 and recent CEO stock sales totaling over $44 million in September 2026. Positive cash flow projection for 2026 supports growth potential despite current net outflow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
